Skip to the main content

Case report, case study

https://doi.org/10.15644/asc57/1/7

Effect of Denosumab Therapy on Pain Level in Diffuse Sclerosing Osteomyelitis of the Mandible: a Case Report

Daniel Jerković ; Department of Maxillofacial Surgery, Clinical Hospital Centre Split, Department of Oral Surgery, School of Medicine, University of Split, Croatia
Kristian Jerković ; Clinical Department of Diagnostic and Interventional Radiology, Clinical Hospital Centre Split, Croatia
Antonella Lesin ; Department of Maxillofacial Surgery, Clinical Hospital Centre Split, Department of Oral Surgery, School of Medicine, University of Split, Croatia
Ana Poljičanin ; Institute of Physical Medicine and Rehabilitation with Rheumatology University Hospital of Split, University Department of Health Studies University of Split, Croatia
Ivan Galić ; Department of Maxillofacial Surgery, Clinical Hospital Centre Split, Department of Oral Surgery, School of Medicine, University of Split, Croatia


Full text: english pdf 1.083 Kb

page 62-69

downloads: 235

cite

Full text: croatian pdf 1.083 Kb

page 62-69

downloads: 93

cite


Abstract

This is the first case report where two patients were under uniform denosumab administration protocol in diffuse sclerosing osteomyelitis (DSO) treatment and were closely monitored for 18 months. Objectives: This study aimed to describe the beneficial effects of denosumab in DSO treatment as well as pain relief and the significant lack of long-term use due to poorer outcomes after repeated use. DSO of the jaw is a poorly understood rare chronic disease the treatment of which is still very challenging despite a rapid development of medicine. Different medical treatments have been pro-posed without any significant long-lasting success. Bisphosphonates have offered substantial clinical benefit in DSO therapy, but due to harmful pharmacodynamic properties, denosumab therapy has been used to replace bisphosphonate therapy. Patients had a reduction in pain intensity with each subsequent application of denosumab but with less success than the first administration of de-nosumab. This case report has shown that denosumab could be a promising conservative treatment option for pain treatment in patients suffering from DSO.

Keywords

Osteomyelitis; Mandible; Pain Management; Denosumab; Pain; Sclerosing Osteomyelitis; Oral Surgery

Hrčak ID:

296291

URI

https://hrcak.srce.hr/296291

Publication date:

27.3.2023.

Article data in other languages: croatian

Visits: 610 *